# Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

> **NCT07150247** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 20 (estimated)

## Conditions studied

- BRAF V600 Colorectal Cancer

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab
- **DRUG:** Bevacizumab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Irinotecan (drug)

## Key facts

- **NCT ID:** NCT07150247
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07150247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07150247, "Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07150247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*